8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Incyte reports 14% revenue growth and raises 2026 sales guidance
Filed with the SEC on · Summarized by InvestorsBot
Incyte reported third-quarter 2026 revenue of $1.56 billion and net sales of $1.32 billion, both up 14% from a year earlier, led by Opzelura sales of $255 million and Hematology and Oncology sales of $235 million. The company raised its 2026 total net sales guidance to $5.21 billion-$5.30 billion, including higher targets for Opzelura and Hematology and Oncology, while reporting a GAAP net loss of $784.8 million, or $3.86 per share, largely due to a $1.23 billion Vega Therapeutics acquisition charge.